Fortrea Holdings is transforming how clinical trials operate through significant digital investments. The company recently launched Fortrea Intelligent Technology (FIT), an AI-enhanced suite designed to automate workflows and streamline clinical trial operations for pharmaceutical sponsors and research sites. This initiative builds upon their existing Xcellerate platform and focuses on integrating AI and machine learning capabilities to improve predictability and agility in clinical research.
This deep transformation creates new dependencies and potential challenges within Fortrea Holdings' systems and data. Critical systems like the Xcellerate platform and various AI-powered applications become central to operations, increasing the importance of data integrity and seamless integration. Risks include data mismatches between integrated platforms, workflow interruptions from AI model failures, and delays in clinical trial progression. This page analyzes specific digital transformation initiatives and the operational breakdowns that sellers can address.
Fortrea Holdings Snapshot
Headquarters: Durham, USA
Number of employees: 14,300
Public or private: Public
Business model: B2B
Website: https://www.fortrea.com
Fortrea Holdings ICP and Buying Roles
Who Fortrea Holdings sells to
- Biopharmaceutical, biotechnology, medical device, and diagnostic companies requiring clinical development solutions.
Who drives buying decisions
-
Chief Information Officer → Sets enterprise technology strategy for clinical trial execution.
-
Chief Operating Officer → Oversees operational efficiency and technology adoption in clinical development.
-
Head of Clinical Development → Directs the implementation of technologies that accelerate clinical trial timelines.
-
Head of Data Science → Manages the integration and utilization of AI/ML models within clinical research workflows.
Key Digital Transformation Initiatives at Fortrea Holdings (At a Glance)
-
Implementing AI-enhanced technology suite for clinical trials workflows.
-
Embedding AI and machine learning into the Xcellerate platform for risk management.
-
Developing an AI Innovation Studio for advanced trial simulations and predictive analytics.
-
Integrating real-time data visualization into clinical pharmacology services.
-
Partnering to use Medidata AI for patient recruitment and diversity in trials.
-
Modernizing digital infrastructure following spin-off to enhance data and analytical capabilities.
Where Fortrea Holdings’s Digital Transformation Creates Sales Opportunities
| Vendor Type | Where to Sell (DT Initiative + Challenge) | Buyer / Owner | Solution Approach |
|---|---|---|---|
| AI/ML Governance Platforms | Implementing AI-enhanced technology suite: AI outputs cause incorrect trial progression decisions. | Chief Information Officer, Head of Data Science | Validate AI model outcomes before workflow automation enforcement. |
| Embedding AI into Xcellerate platform: predictive signals incorrectly flag low-risk activities. | Chief Operating Officer, Head of Clinical Development | Calibrate AI models to accurately identify high-risk events. | |
| Developing an AI Innovation Studio: generated trial simulations contain inaccurate parameters. | Head of Data Science, Head of Clinical Development | Enforce data quality checks on simulation inputs and outputs. | |
| Data Integration & Quality Platforms | Implementing AI-enhanced technology suite: data synchronization fails between new AI tools and Xcellerate. | Chief Information Officer, Head of Data Science | Standardize data formats across disparate clinical systems. |
| Integrating real-time data visualization: ancillary data sources do not refresh within 24 hours. | Head of Data Science, Head of Clinical Operations | Prevent data latency issues in dashboards through automated pipelines. | |
| Modernizing digital infrastructure: transaction data fails to transfer during ERP transitions. | Chief Information Officer, IT Operations Lead | Validate data migration and ensure system interoperability post-transition. | |
| Workflow Automation & Orchestration | Implementing AI-enhanced technology suite: automated clinical trial workflows stall due to system dependencies. | Chief Operating Officer, Head of Clinical Operations | Route tasks dynamically based on clinical trial progression rules. |
| Embedding AI into Xcellerate platform: automated workflows initiate incorrect actions based on faulty signals. | Head of Clinical Development, VP of Quality Assurance | Validate automated actions against predefined clinical protocols. | |
| Partnering to use Medidata AI: patient enrollment workflows halt when diversity data is inconsistent. | Head of Patient Recruitment, Head of Clinical Development | Standardize patient data attributes for seamless cross-platform use. | |
| Clinical Trial Optimization Platforms | Partnering to use Medidata AI: study feasibility models inaccurately predict patient recruitment rates. | Head of Clinical Development, Head of Patient Recruitment | Calibrate prediction models with real-world patient population data. |
| Integrating real-time data visualization: anomalies in trial data are not highlighted promptly. | Head of Data Science, Clinical Project Manager | Detect data anomalies through automated monitoring and alerting. | |
| Developing an AI Innovation Studio: complex data processes require manual intervention for pattern recognition. | Head of Data Science, Clinical Project Manager | Automate data pattern recognition for faster insights. |
Identify when companies like Fortrea Holdings are in-market for your solutions.
Spot buying signals, find the right prospects, enrich your data, and reach out with relevant messaging at the right time.
What makes this Fortrea Holdings’s digital transformation unique
Fortrea Holdings prioritizes digital transformation by directly embedding AI and machine learning into their core clinical trial platforms. This approach focuses on enhancing specific clinical workflows, such as risk management and data visualization, rather than generalized technology adoption. Their strategy uniquely aims to transform complex clinical development into clear, actionable insights for diverse stakeholders globally. This makes their transformation critical for maintaining compliance and accelerating therapy delivery to patients.
Fortrea Holdings’s Digital Transformation: Operational Breakdown
DT Initiative 1: AI-Enhanced Clinical Trial Technology Suite
What the company is doing
Fortrea Holdings implements Fortrea Intelligent Technology (FIT), an AI-enhanced suite of solutions. This suite automates workflows and streamlines clinical trial operations across various applications. It specifically addresses clinical pharmacology, development, and medical device development.
Who owns this
-
Chief Information Officer
-
Chief Operating Officer
-
Head of Clinical Development
Where It Fails
-
AI outputs from the Lifecycle solutions cause incorrect trial progression decisions.
-
Automated workflows in the FIT suite halt due to unexpected data format changes.
-
Persona-driven tools provide irrelevant insights when user roles change.
-
Integration failures prevent seamless data flow between FIT components.
Talk track
Noticed Fortrea Holdings is rolling out its AI-enhanced clinical trial technology suite. Been looking at how some CROs are validating AI outputs against predefined benchmarks instead of solely relying on automated decisions, can share what’s working if useful.
DT Initiative 2: Embedding AI and ML into Xcellerate Platform
What the company is doing
Fortrea Holdings integrates AI and machine learning capabilities into its Xcellerate platform. This platform handles Risk-Based Quality Management, Central Monitoring, and Oversight functions. It generates predictive signals and initiates automated workflows for clinical trials.
Who owns this
-
Head of Data Science
-
VP of Quality Assurance
-
Head of Clinical Operations
Where It Fails
-
Predictive signals incorrectly flag low-risk clinical trial activities.
-
Automated workflows initiate inappropriate actions based on faulty AI signals.
-
Risk-Based Quality Management models fail to adapt to new study protocols.
-
Central Monitoring dashboards display inconsistent data across different study views.
Talk track
Saw Fortrea Holdings is embedding AI and ML into their Xcellerate platform. Been looking at how some teams are continuously calibrating their risk models with real-world outcomes instead of using static parameters, happy to share what we’re seeing.
DT Initiative 3: AI Innovation Studio Development
What the company is doing
Fortrea Holdings establishes an AI Innovation Studio to develop and deploy AI and ML technologies. This studio focuses on cutting-edge processes like trial simulations and predictive analytics. It also addresses repetitive administrative tasks, freeing up human creativity.
Who owns this
-
Chief Information Officer
-
Head of Data Science
-
VP of AI and Machine Learning
Where It Fails
-
AI-powered trial simulations produce inaccurate projections due to incomplete historical data.
-
Predictive analytics models fail to identify critical patterns in complex trial data.
-
Smartphone-enabled data collection systems cause data integrity issues upon ingestion.
-
Specialized large language models generate inconsistent text for protocol documentation.
Talk track
Looks like Fortrea Holdings is building out its AI Innovation Studio for advanced clinical trial capabilities. Been seeing teams enforce strict validation of AI-generated outputs before they influence core trial processes, can share what’s working if useful.
DT Initiative 4: Real-Time Data Visualization
What the company is doing
Fortrea Holdings integrates real-time data visualization into its clinical pharmacology services. This leverages combined eSource and EDC platforms to provide live access to study data. It supports sponsors in monitoring data, identifying trends, and making informed decisions.
Who owns this
-
Head of Data Science
-
Head of Clinical Operations
-
Clinical Project Manager
Where It Fails
-
Ancillary data sources do not update within the required 24-hour window for dashboards.
-
Data visualization dashboards display conflicting information from different data streams.
-
The centralized clinical data dashboard fails to integrate specific protocol-aligned endpoints.
-
Direct source connectivity to ClinSpark® encounters intermittent data refresh failures.
Talk track
Seems like Fortrea Holdings is focusing on real-time data visualization for clinical pharmacology. Been looking at how some research organizations are implementing automated data validation at the source instead of correcting inconsistencies downstream, can share what’s working if useful.
Who Should Target Fortrea Holdings Right Now
This account is relevant for:
-
AI Model Governance and Validation Platforms
-
Clinical Data Integration and Quality Solutions
-
Workflow Automation Platforms for Life Sciences
-
Clinical Trial Optimization and Predictive Analytics Vendors
-
eClinical Data Management Systems
Not a fit for:
-
Generic IT Staffing Agencies
-
Basic CRM Software Providers
-
Consumer-focused AI Applications
-
Unaffiliated Hardware Vendors
When Fortrea Holdings Is Worth Prioritizing
Prioritize if:
-
You sell tools for AI model validation that prevent incorrect clinical trial progression decisions.
-
You sell solutions for data standardization across disparate clinical systems to resolve synchronization failures.
-
You sell workflow automation platforms that prevent clinical trial tasks from stalling due to system dependencies.
-
You sell data quality platforms that detect and correct anomalies in real-time clinical trial dashboards.
-
You sell predictive analytics calibration tools that ensure accurate patient recruitment rate forecasts.
Deprioritize if:
-
Your solution does not address any of the specific breakdowns described above.
-
Your product is limited to basic data storage with no advanced integration capabilities.
-
Your offering is not built for the highly regulated and complex clinical research environment.
Who Can Sell to Fortrea Holdings Right Now
AI Model Governance and Validation Platforms
Credo AI - This company provides an AI governance platform that helps organizations build, deploy, and monitor responsible AI systems.
Why they are relevant: AI outputs cause incorrect trial progression decisions within Fortrea Holdings' new technology suite. Credo AI can validate these AI models, ensuring their outcomes align with clinical protocols and prevent erroneous actions.
Gretel.ai - This company offers a platform for generating synthetic data, enabling privacy-preserving development and testing of AI models.
Why they are relevant: AI-powered trial simulations produce inaccurate projections due to incomplete historical data at Fortrea Holdings. Gretel.ai can generate high-quality synthetic data for more robust model training and validation, improving simulation accuracy without compromising patient privacy.
Aindo - This company develops synthetic data solutions that protect sensitive information while enabling advanced analytics and AI development.
Why they are relevant: Fortrea Holdings' AI Innovation Studio requires reliable data for advanced trial simulations but faces data privacy constraints. Aindo's synthetic data ensures secure development, allowing more accurate predictive analytics without exposing patient records.
Clinical Data Integration and Quality Solutions
Informatica - This company provides an enterprise cloud data management platform that helps organizations integrate, manage, and govern data.
Why they are relevant: Data synchronization fails between Fortrea Holdings' new AI tools and the Xcellerate platform. Informatica can establish robust data pipelines and enforce data quality rules, ensuring consistent and reliable information flow across clinical systems.
Talend - This company offers a data integration and data governance platform that simplifies data management across complex environments.
Why they are relevant: Ancillary data sources do not refresh within the required timeframes for Fortrea Holdings' real-time dashboards. Talend can automate data integration processes, guaranteeing timely and accurate data delivery for critical clinical insights.
Collibra - This company provides a data intelligence platform that helps organizations understand and trust their data.
Why they are relevant: Fortrea Holdings' Xcellerate platform experiences inconsistent data across different study views. Collibra can establish comprehensive data governance, providing a single source of truth and improving data reliability for central monitoring.
Workflow Automation Platforms for Life Sciences
Appian - This company offers a low-code automation platform that helps organizations build business applications and automate complex workflows.
Why they are relevant: Automated clinical trial workflows within Fortrea Holdings' FIT suite stall due to system dependencies. Appian can design agile, adaptive workflows that dynamically route tasks, ensuring smooth progression even with complex interdependencies.
Pega Systems - This company provides an AI-powered decisioning and workflow automation platform for complex enterprise operations.
Why they are relevant: Automated workflows on Fortrea Holdings' Xcellerate platform initiate inappropriate actions based on faulty AI signals. Pega Systems can embed decision logic to validate actions against clinical protocols before execution, preventing errors in automated processes.
ServiceNow - This company offers a cloud-based platform that automates enterprise IT workflows and business processes.
Why they are relevant: Fortrea Holdings' new AI tools require seamless integration into existing IT operations but face integration failures. ServiceNow can orchestrate IT workflows, ensuring new clinical technologies integrate smoothly and operate without disruption.
Clinical Trial Optimization and Predictive Analytics Vendors
Medidata Solutions - This company provides a unified platform for clinical research, including data capture, management, and analytics.
Why they are relevant: Fortrea Holdings utilizes Medidata AI, but their study feasibility models inaccurately predict patient recruitment rates. Medidata’s advanced analytics can calibrate these models with more extensive real-world data, providing more accurate recruitment forecasts.
CluePoints - This company offers a risk-based monitoring and data quality oversight platform for clinical trials.
Why they are relevant: Fortrea Holdings' predictive signals within Xcellerate incorrectly flag low-risk clinical activities. CluePoints can refine risk-based monitoring parameters, ensuring that predictive signals accurately identify genuine risks in trial data.
IQVIA Technologies - This company provides a range of technology solutions for clinical development, including predictive analytics and patient engagement.
Why they are relevant: Fortrea Holdings' AI Innovation Studio seeks to enhance trial simulations but encounters challenges with data complexity. IQVIA Technologies can provide advanced predictive analytics capabilities to process complex datasets, improving the accuracy of trial outcomes.
Final Take
Fortrea Holdings is rapidly scaling its AI-enhanced clinical trial technology and integrating these capabilities across core platforms like Xcellerate. Breakdowns are visible in AI model reliability, data synchronization across complex systems, and the precision of predictive analytics. This account represents a strong fit for vendors who can validate AI outputs, ensure seamless clinical data flow, and provide robust workflow orchestration in a highly regulated environment.
Identify buying signals from digital transformation at your target companies and find those already in-market.
Find the right contacts and use tailored messages to reach out with context.